EMMA
Emmaus Life Sciences, Inc.
- PER (TTM)
- -
- PER (Forward)
- -0.14
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.01
- 시가총액
- 701,882
- 배당수익률
- -
- 베타
- 9.36
- 1개월 수익률
- 0.00%
- 3개월 수익률
- -28.06%
- 6개월 수익률
- -15.97%
- 1년 수익률
- -23.08%
- 2년 수익률
- -
- 5일 평균거래량
- 151942
- 60일 평균거래량
- 41378
- 1년 평균거래량
- 40333
- 5d/60d 거래량 비율
- 3.67×
- 60d/1y 거래량 비율
- 1.03×
- 변동성(60일, 연환산)
- 90.53%
- BB 스퀴즈 스코어
- 0.59
- SMA50 비율
- 0.82
- SMA200 비율
- 0.82
- RSI (14)
- 47
- 20일 수렴도
- 0.06
- 52주 최고
- 0.02
- 52주 최저
- 0.01
- 고점 대비
- -49.75%
- 저점 대비
- 19.05%
펀더멘털 갱신: 2026-05-10T08:46:45+00:00 · 시세 갱신: 2026-05-10T06:30:05+00:00
회사 정보
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.